EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case report: Targeted treatment strategies for Erdheim-Chester disease

Anita Gulyás, László Imre Pinczés, János Mátyus, Edit Végh, Judit Bedekovics, Judit Tóth, Sándor Barna, Zsolt Hunya, Imre Lőrinc Szabó, Annamária Gazdag, Árpád Illés, Ferenc Magyari

Frontiers in Oncology · 14.03.2024 · 14

DOI: 10.3389/fonc.2024.1305518 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 14.03.2024. Verfasst von Anita Gulyás und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Erdheim-Chester disease (ECD) is a rare disease that belongs to the group of Dendritic and histiocytic neoplasms. Only 2000 cases have been reported worldwide. It can present with a wide range of symptoms, making a differential diagnosis especially difficult. The primary and most important diagnostic tool is a biopsy of the affected organ/tissue. Nowadays the analysis of different mutations affecting the BRAF and MAPK pathways makes it possible to use targeted treatments, such as vemurafenib, dabrafenib, or cobimetinib.

Objective

Our aim is to present the results of three male patients treated in our hematology department.

Results

Our BRAF mutation-positive patient presented with retroperitoneal tissue proliferation and diabetes insipidus. The initial therapy of choice was dabrafenib. After 3 months of treatment, 18 F-fluoro-deoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT) scans showed regression, and after 2 years of treatment, no disease activity was detected. In our second patient, a recurrent febrile state (not explained by other reasons) and diabetes insipidus suggested the diagnosis. A femoral bone biopsy confirmed BRAF-negative ECD. The first-line therapy was interferon-alpha. After 3 months of treatment, no response was observed on 18 FDG-PET/CT, and treatment with cobimetinib was started. The control 18 FDG-PET/CT imaging was negative. Our third patient was evaluated for dyspnea, and a CT scan showed fibrosis with hilar lymphadenomegaly. A lung biopsy confirmed BRAF-negative ECD. We started treatment with interferon-alpha, but unfortunately, no improvement was observed. Second-line treatment with cobimetinib resulted in a partial metabolic response (PMR) according to control 18 FDG-PET/CT.

Conclusions

Our results demonstrate that an appropriately chosen treatment can lead to a good therapeutic response, but dose reduction may be necessary due to side effects. With advanced targeted therapeutic treatment options, survival and quality of life are significantly improved.

Schlagwörter

Stichwörter der Autor:innen

BRAF inhibitorsErdheim-Chester disease (ECD)PET/CTcobimetinibhistiocytosisinterferon alphamyeloid neoplasm

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Doctoral School of Clinical Medicine, University of Debrecen, Debrecen, Hungary.
  • Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Zitieren

APA

Gulyás, A., Pinczés, L. I., Mátyus, J., Végh, E., Bedekovics, J., Tóth, J., Barna, S., Hunya, Z., Szabó, I. L., Gazdag, A., Illés, Á., & Magyari, F. (2024). Case report: Targeted treatment strategies for Erdheim-Chester disease. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1305518

Vancouver

Gulyás A, Pinczés LI, Mátyus J, Végh E, Bedekovics J, Tóth J, et al. Case report: Targeted treatment strategies for Erdheim-Chester disease. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1305518

BibTeX
@article{Gulys2024,
  author = {Gulyás, Anita and Pinczés, László Imre and Mátyus, János and Végh, Edit and Bedekovics, Judit and Tóth, Judit and Barna, Sándor and Hunya, Zsolt and Szabó, Imre Lőrinc and Gazdag, Annamária and Illés, Árpád and Magyari, Ferenc},
  title = {Case report: Targeted treatment strategies for Erdheim-Chester disease},
  journal = {Frontiers in Oncology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fonc.2024.1305518}
}
Kostenlos starten →